Multi-Theme Courses

Each volume contains valuable lessons on a variety of topics important to your practice.  Three interesting volumes are available from which to choose. 
Please pay special attention to expiration dates.  

Volume 35 (2009)

4.0 Contact Hours Each (4.0 CEUs)
Knowledge-Based CPE Activity
Release Date: 03/2009 - Expiration Date: 03/2012

Note: Unless otherwise disclosed, all Authors report having no real or potential conflict of interest in relation to this course. ALL authors of these courses have signed a conflict of interest statement to ensure that any information in the course is fair and balanced.

1. Updates in the Management of Allergic Rhinitis and Conjunctivitis 018-999-09-701-H01-P
   Nina Yen, PharmD, Primary Care Resident, University of Connecticut School of Pharmacy and Devra K. Dang, PharmD, BCPS, CDE, Assistant Clinical Professor, University of Connecticut School of Pharmacy
   Learning Objectives 1) Describe the pathophysiology of allergic rhinitis & conjunctivitis. 2) Distinguish between the different classifications of allergic rhinitis and recognize conditions that can be considered in the differential diagnosis. 3) Identify non-pharmacologic treatment options for the management of allergic rhinitis and conjunctivitis. 4) Describe specific therapeutic characteristics of drug treatment options for allergic rhinitis and conjunctivitis. 5) Formulate a treatment plan and identify appropriate patient education points based on treatment guidelines and patient specific factors.
2. Incorporating Management and Law into Pharmacy Practice: Practical Tips for Pharmacists 018-999-09-702-H03-P
   Alan R. Spies, R.Ph., J.D., M.B.A., Ph.D., Assistant Professor of Pharmacy Administration, Southwestern Oklahoma State University College of Pharmacy
   Learning Objectives 1) Describe the role of management in pharmacy practice, regardless of practice setting. 2) Recognize the legal implications involved with interviewing, hiring, firing and conducting performance evaluations. 3) Illustrate appropriate ways of handling an employee pharmacist who makes a medication error. 4) Identify workplace pitfalls that lead to a potential discrimination lawsuit.
3. A Review of Recently Approved Drugs 018-999-09-703-H01-P
   Carroll L. Ramos, R.Ph., Ph.D., Professor of Pharmacology, Southwestern Oklahoma State University College of Pharmacy
   Learning Objectives 1) Identify the pharmacological and/or therapeutic classification. 2) Describe the approved indication. 3) Recognize the basic mechanism of action. 4) Describe common adverse effects. 5) Recognize clinically relevant drug interactions. 6) Illustrate important patient information. 7) Recognize an appropriate dosage regimen.
4. The Role of Nonprescription Products in Pain Management 018-999-09-704-H01-P
   W. Steven Pray, Ph.D., D.Ph., Bernhardt Professor of Nonprescription Products and Devices, Southwestern Oklahoma State University College of Pharmacy Disclosure: The author of this course has reported a financial relationship with Procter & Gamble as well as Hisamitsu, Inc. Please note the author of this course has agreed and signed a conflict of interest statement to ensure that any information in this course is fair and balanced. Additionally, the course reviewer has agreed and signed an agreement stating that information in this course is fair and balanced, noncommercialized, objective and that course content is valid and aligned with the interest of the public, is not promotional and does not appear to endorse a specific commercial drug/product/service.
   Learning Objectives 1) Recognize various pain-producing conditions that are amenable to self-therapy, such as headache, muscular injury and tendon damage, and differentiate them from conditions requiring physician care. 2) Recognize the various decision points at which patients should be referred to a physician. 3) Determine which nonprescription products and devices are appropriate for self-therapy. 4) Appropriately counsel patients when recommending nonprescription products and devices for pain.

Volume 34 (2008)

4.0 Contact Hours Each (4.0 CEUs)
Release Date: 03/2008 - Expiration Date: 03/2011

Note: Unless otherwise disclosed, all Authors report having no real or potential conflict of interest in relation to this course. ALL authors of these courses have signed a conflict of interest statement to ensure that any information in the course is fair and balanced.

1. Pharmacist-Delivered Tobacco Cessation. 018-999-08-701-H01-P
   Larry A. Dent, Pharm.D., BCPS, University of Montana Skaggs School of Pharmacy Disclosure: Author of this course has served on the speaker's bureau of Pfizer.
   Learning Objectives 1) Describe the prevalence and epidemiology of tobacco use as well as health risks, environmental effects, and economic burden associated with tobacco use. 2) List the benefits of smoking cessation for health and well-being, and list the various components of nicotine addiction. 3) Apply tobacco cessation strategies such as clinical practice guidelines, and counsel to assist patients in selecting appropriate pharmacotherapy. 4) Recognize the benefits, appropriate use, side effects, duration, and monitoring of individual drug therapies and identify the various components of cognitive and behavioral change counseling.
2. Patient Centered Care: Pharmacist Adult Vaccination. 018-999-08-702-H01-P
   Beverly A. Sullivan, Pharm.D. & Kerri Kilgore, Pharm.D., University of Wyoming School of Pharmacy Learning Objectives 1) Identify current CDC recommended adult vaccines, their storage, overall vaccination safety and the management of adverse effects. 2) Recognize and describe the proper administration of vaccinations in adults. 3) Describe the process used to screen adults seeking vaccination and to document their administration. 4) Identify pharmacist liability in the provision of adult vaccinations.
3. Principles of Obesity Management and Weight Control. 018-999-08-703-H01-P
   Judy T. Chen, Pharm.D., BCPS, Purdue University School of Pharmacy; Devra K. Dang, Pharm.D., University of Connecticut School of Pharmacy; & Amy Heck Sheehan, Pharm.D., Purdue University School of Pharmacy Learning Objectives 1) Describe the epidemiological impact and discuss the health implications of overweight and obesity. 2) Demonstrate an understanding of current theories regarding the development of obesity, and identify the diagnostic criteria for classification of overweight and obesity. 3) Assess patients risk-status and develop treatment goals for weight loss and weight maintenance, evaluating the role of nonpharmacological interventions, dietary supplements, and surgery. 4) Appraise the role of pharmacological interventions in weight loss therapy based on patient-specific characteristics, designing an appropriate treatment plan and treatment-specific monitoring plan.
4. Counseling Patients with Minor Dermatological Conditions. 018-999-08-704-H01-P
   W. Steven Pray, Ph.D., D.Ph., Southwestern Oklahoma State University College of Pharmacy Learning Objectives 1) Recognize various dermatological conditions. 2) Identify patients with dermatological conditions that are amenable to self-therapy, and those that require referral to a physician. 3) Choose appropriate nonprescription therapy for various dermatological conditions. 4) Appropriately counsel patients when recommending nonprescription products for dermatological conditions.

Volume 33 (2007)

4.0 Contact Hours Each (4.0 CEUs)
Release Date: 03/2007 - Expiration Date: 03/2010

Note: Unless otherwise disclosed, all Authors report having no real or potential conflict of interest in relation to this course. ALL authors of these courses have signed a conflict of interest statement to ensure that any information in the course is fair and balanced.

1. New Drugs: A Practical Guide for Pharmacists. 018-999-07-701-H01-P
   Carroll L. Ramos, R.Ph., Ph.D., Southwestern Oklahoma State University, Weatherford, OK
   Learning Objectives: 1) Identify the pharmacological and/or therapeutic classification. 2) Describe the approved indication. 3) Understand the basic mechanism of action. 4) Describe common adverse effects. 5) Recognize clinically relevant drug interactions. 6) Discuss important patient information. 7) Recognize an appropriate dosage regimen.
2. New Therapeutic Options in the Management of Type 2 Diabetes. 018-999-07-702-H01-P
   Betsy Carlisle, Pharm.D., CDE, Brackenridge Hospital, Austin, Texas (Disclosure: The author does have an affiliation with Pfizer and sanofi-aventis.)
   Learning Objectives 1) Identify the action patterns of the newer insulins: detemir (Levemir), glulisine (Apidra) and inhaled insulin (Exubera) and their role in basal-bolus insulin regimens. 2) Understand the role of the new incretin mimetic exenatide (Byetta) in addressing insulin resistance and beta-cell dysfunction. 3) Describe the potential for pramlintide (Symlin), a synthetic amylin analogue, to complement the action of insulin by reducing glucagon secretion, affecting satiety and slowing gastrointestinal emptying.
3. Therapeutic Strategies for Hypertension. 018-999-07-703-H01-P
   Alan J. Zillich, PharmD, Purdue University, Indianapolis, IN
   Learning Objectives 1) Delineate the epidemiologic impact of hypertension on society. 2) Understand hypertension pathophysiology and related clinical sequelae. 3) Identify the stages of hypertension outlined by the Seventh Joint National Committee on the Prevention, Detection, and Treatment of High Blood Pressure (JNC-7). 4) Compare and contrast the mechanisms of action for antihypertensive medications. 5) Construct treatment plans for a patient with hypertension and concomitant disease states. 6) Evaluate patient-specific information and scientific evidence to support appropriate pharmacologic and non-pharmacologic therapies. 7) Develop monitoring plans for a patient with hypertension. 8) Discuss specific educational messages for a patient with hypertension.
4. The Metabolic Syndrome. 018-999-07-704-H01-P
   Joan M. Rider, B.S., PharmD., BCPS, CDE, FMPA, Ferris State University, Grand Rapids, MI
   Learning Objectives 1) Define the Metabolic Syndrome (MetS) and its relationship to the development and management of cardiovascular disease and type 2 diabetes mellitus. 2) Discuss the health factors that make up the MetS. 3) Deliberate the role of inflammation, thrombosis and high sensitivity-complement reactive protein (hs-CRP) in the MetS. 4) Determine aggressive treatment options for the abnormal health components that lead to Cardiometabolic Risk (CMR).

Single-Theme Courses

NONE CURRENTLY AVAILABLE